DE602005021702D1 - 2-methylen-19-nor-1alpha-hydroxy-17-enhormopregnacalziferol und anwendungen davon - Google Patents

2-methylen-19-nor-1alpha-hydroxy-17-enhormopregnacalziferol und anwendungen davon

Info

Publication number
DE602005021702D1
DE602005021702D1 DE602005021702T DE602005021702T DE602005021702D1 DE 602005021702 D1 DE602005021702 D1 DE 602005021702D1 DE 602005021702 T DE602005021702 T DE 602005021702T DE 602005021702 T DE602005021702 T DE 602005021702T DE 602005021702 D1 DE602005021702 D1 DE 602005021702D1
Authority
DE
Germany
Prior art keywords
skin
compound
methylene
dehydro
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005021702T
Other languages
English (en)
Inventor
Hector F Deluca
Bulli Padmaja Tadi
Lori A Plum
Margaret Clagett-Dame
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wisconsin Alumni Research Foundation
Original Assignee
Wisconsin Alumni Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Research Foundation filed Critical Wisconsin Alumni Research Foundation
Publication of DE602005021702D1 publication Critical patent/DE602005021702D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
DE602005021702T 2004-11-22 2005-11-18 2-methylen-19-nor-1alpha-hydroxy-17-enhormopregnacalziferol und anwendungen davon Active DE602005021702D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63000704P 2004-11-22 2004-11-22
PCT/US2005/041820 WO2006057901A2 (en) 2004-11-22 2005-11-18 2-METHYLENE-19-NOR-1α-HYDROXY-17-ENE-HOMOPREGNACALCIFEROL AND ITS USES

Publications (1)

Publication Number Publication Date
DE602005021702D1 true DE602005021702D1 (de) 2010-07-15

Family

ID=36216285

Family Applications (3)

Application Number Title Priority Date Filing Date
DE602005020842T Active DE602005020842D1 (de) 2004-11-22 2005-11-18 17,20(e)-dehydro-vitamin-d-analoga und deren verwendungen
DE602005021702T Active DE602005021702D1 (de) 2004-11-22 2005-11-18 2-methylen-19-nor-1alpha-hydroxy-17-enhormopregnacalziferol und anwendungen davon
DE602005021538T Active DE602005021538D1 (de) 2004-11-22 2005-11-18 17,20(z)-dehydro-vitamin-d-analoge und deren verwendungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE602005020842T Active DE602005020842D1 (de) 2004-11-22 2005-11-18 17,20(e)-dehydro-vitamin-d-analoga und deren verwendungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE602005021538T Active DE602005021538D1 (de) 2004-11-22 2005-11-18 17,20(z)-dehydro-vitamin-d-analoge und deren verwendungen

Country Status (11)

Country Link
US (6) US7241748B2 (de)
EP (3) EP1828114B1 (de)
JP (3) JP5043673B2 (de)
AT (3) ATE465144T1 (de)
AU (3) AU2005309805B2 (de)
CA (3) CA2588410C (de)
DE (3) DE602005020842D1 (de)
ES (3) ES2347058T3 (de)
MX (3) MX2007006262A (de)
NZ (3) NZ555277A (de)
WO (3) WO2006057901A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030188756A1 (en) * 2002-08-19 2003-10-09 Cantorna Margherita T Treatment of inflammatory bowel disease with vitamin d compounds
US8404667B2 (en) * 2006-12-29 2013-03-26 Wisconsin Alumni Research Foundation Compounds, compositions, kits and methods of use to orally and topically treat acne and other skin conditions by 19-Nor vitamin D analog
US7241748B2 (en) * 2004-11-22 2007-07-10 Wisconsin Alumni Research Foundation 17,20(Z)-dehydro vitamin D analogs and their uses
CA2588415C (en) * 2004-11-22 2012-07-10 Wisconsin Alumni Research Foundation 2-methylene-19,26,27-trinor-(20s)-1-alpha-hydroxyvitamin d3 and its uses
CA2676512A1 (en) * 2007-01-25 2008-07-31 Bioxell S.P.A. Synthesis of 1.alpha.-fluoro-25-hydroxy-16-23e-diene-26,27-bishomo-20-epi-cholecalciferol
US7893043B2 (en) * 2008-07-10 2011-02-22 Wisconsin Alumni Research Foundation 2-methylene-(17Z)-17(20)-dehydro-19,21-dinor-vitamin D analogs
US7888339B2 (en) * 2008-07-10 2011-02-15 Wisconsin Alumni Research Foundation 2-methylene-20(21)-dehydro-19-nor-vitamin D analogs
EP2387407A4 (de) * 2009-01-16 2012-06-27 Pharmaceutical Compounding Nz Ltd Medikament zur behandlung von schmerzen und entzündungen
WO2011011706A2 (en) * 2009-07-24 2011-01-27 The Johns Hopkins University Methods and compositions for treating or preventing autoimmune diseases using immunomodulatory agents
US8445468B2 (en) * 2009-10-02 2013-05-21 Wisconsin Alumni Research Foundation (20S,22E)-2-methylene-19-nor-22-ene-1α,25-dihydroxyvitamin D3
US8664206B2 (en) 2010-03-23 2014-03-04 Wisconsin Alumni Research Foundation Diastereomers of 2-methylene-19-nor-22-methyl-1α,25-dihydroxyvitamin D3
WO2011119610A2 (en) * 2010-03-23 2011-09-29 Wisconsin Alumni Research Foundation (20S)-2-METHYLENE-19-NOR-22-DIMETHYL-1α,25- DIHYDROXYVITAMIN D3 AND (20R)-2-METHYLENE-19-NOR-22- DIMETHYL-1α,25-HYDROXYVITAMIN D3
US20110237557A1 (en) * 2010-03-23 2011-09-29 Deluca Hector F Diastereomers of 2-methylene-19-nor-22-methyl-1alpha,25-dihydroxyvitamin d3
JP6114292B2 (ja) * 2011-10-21 2017-04-12 ウイスコンシン アラムニ リサーチ ファンデーション ２−メチレン−ビタミンｄ類似体およびそれらの使用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666634A (en) * 1984-12-05 1987-05-19 Chugai Seiyaku Kabushiki Kaisha vitamin D3 derivatives having a substituent at 2-position
US5145846A (en) * 1988-01-20 1992-09-08 Hoffmann-La Roche Inc. Vitamin D3 analogs
US5362719A (en) * 1990-03-01 1994-11-08 Leo Pharmaceutical Products, Ltd. A/S Lovens Kemiske Fabrik Produktionsaktieselskab) Use of vitamin-D analogues in the treatment of acne
GB9004544D0 (en) * 1990-03-01 1990-04-25 Leo Pharm Prod Ltd Novel treatment ii
ATE116859T1 (de) * 1990-07-04 1995-01-15 Marcin Krotkiewski Blutdrucksenkendes präparat.
US5086191A (en) * 1991-05-28 1992-02-04 Wisconsin Alumni Research Foundation Intermediates for the synthesis of 19-nor vitamin D compounds
GB9214202D0 (en) * 1992-07-03 1992-08-12 Leo Pharm Prod Ltd Chemical compounds
DE69400495T2 (de) * 1993-04-05 1997-04-30 Wisconsin Alumni Res Found 19-Nor-vitamin-D3-Verbindung mit einem Substituent an die 2. Stelle
US5552392A (en) * 1993-11-03 1996-09-03 Wisconsin Alumni Research Foundation Method of treating hypoparathyroidism with (20S) vitamin D compounds
DE69508895T2 (de) 1994-12-14 1999-10-21 Duphar Int Res Vitamin-D-Derivate und Verfahren zur Herstellung dieser Verbindungen
GB9625271D0 (en) * 1996-12-04 1997-01-22 Leo Pharm Prod Ltd Chemical compounds
HUP0002454A2 (hu) * 1997-02-13 2000-12-28 Bone Care International, Inc. D-Vitamin-molekularésszel rendelkező konjugátumok és ilyen konjugátumokat tartalmazó gyógyászati készítmények
US6392071B1 (en) * 1997-03-17 2002-05-21 Wisconsin Alumni: Research Foundation 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds
US6316642B1 (en) * 1997-03-17 2001-11-13 Wisconsin Alumni Research Foundation 26,27-Homologated-20-EPI-2alkyl-19-nor-vitamin D compounds
US5843928A (en) * 1997-03-17 1998-12-01 Wisconsin Alumni Research Foundation 2-alkylidene-19-nor-vitamin D compounds
US5945410A (en) 1997-03-17 1999-08-31 Wisconsin Alumni Research Foundation 2-alkyl-19-nor-vitamin D compounds
US6306844B1 (en) * 1997-03-17 2001-10-23 Wisconsin Alumni Research Foundation Use of 2α-methyl-19-nor-20(S)-1α, 25-dihydroxyvitamin D3 to increase bone strength
US5936105A (en) * 1997-06-13 1999-08-10 Tetrionics, Inc. 14-EPI-19-nor-vitamin D compounds and methods
AU743399B2 (en) * 1997-06-25 2002-01-24 Teijin Limited Vitamin d3 derivatives and remedies for inflammatory respiratory diseases prepared from the same
GB9721156D0 (en) * 1997-10-06 1997-12-03 Leo Pharm Prod Ltd Novel vitamin d analogues
AU762481C (en) * 1998-03-27 2004-08-19 Oregon Health Sciences University Vitamin D and its analogs in the treatment of tumors and other hyperproliferative disorders
JP4022141B2 (ja) * 2000-05-31 2007-12-12 ウィスコンシン・アルムニ・リサーチ・ファウンデーション ２−エチル及び２−エチリデン−１９−ノル−ビタミンｄ化合物
WO2002006218A2 (en) * 2000-07-18 2002-01-24 Bone Care International, Inc. STABILIZED 1α-HYDROXY VITAMIN D
NZ524657A (en) * 2000-09-08 2004-12-24 Wisconsin Alumni Res Found 1 alpha-hydroxy-2-methylene-19-nor-homopregnacalciferol and its therapeutic applications
AU2002314056A1 (en) 2001-05-22 2002-12-03 Bioxell S.P.A. Use of a vitamin d3 analogue for the treatment of autoimmune diabetes
US6627622B2 (en) * 2002-02-18 2003-09-30 Wisconsin Alumni Research Foundation (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses
US6566352B1 (en) * 2002-02-18 2003-05-20 Wisconsin Alumni Research Foudation 1 α-hydroxy-2-methylene-19-nor-pregnacalciferol and its uses
KR20040095237A (ko) * 2002-03-29 2004-11-12 위스콘신 얼럼나이 리서어치 화운데이션 1α-히드록시-2-메틸렌-19-노르-호모프레그나칼시페롤의합성 방법
US6846811B2 (en) * 2002-04-22 2005-01-25 Wisconsin Alumni Research Foundation (20S) 1α-hydroxy-2α-methyl and 2β-methyl-19-nor-vitamin D3 and their uses
GB0305332D0 (en) 2003-03-10 2003-04-09 Leuven K U Res & Dev Biological evaluation of novel vitamin D analogues
US20050009792A1 (en) 2003-07-08 2005-01-13 Deluca Hector F. (20S)-1alpha-hydroxy-2-methylene-19-nor-vitamin D3 and its uses
MXPA06005887A (es) * 2003-11-25 2006-06-27 Wisconsin Alumni Res Found Analogos de vitamina d para la prevencion y el tratamiento de la obesidad.
EP1694333A2 (de) * 2003-11-25 2006-08-30 Deltanoid Pharmaceuticals, Inc. Verfahren zur reduzierung des körperfetts mit vitamin-d-verbindungen
US7241748B2 (en) * 2004-11-22 2007-07-10 Wisconsin Alumni Research Foundation 17,20(Z)-dehydro vitamin D analogs and their uses
AU2005309789A1 (en) 2004-11-22 2006-06-01 Wisconsin Alumni Research Foundation 2alpha-methyl and 2beta-methyl analogs of 19,26,27-trinor-(20S)-1alpha-hydroxyvitamin D3 and their uses
WO2008035207A2 (en) 2006-04-06 2008-03-27 Wisconsin Alumni Research Foundation 2-methylene-1alpha-hydroxy-19,21-dinorvitamin d3 analogs and uses thereof
KR101495578B1 (ko) * 2007-04-25 2015-02-25 사이토크로마 인코포레이티드 비타민 ｄ 부족 및 결핍의 치료 방법

Also Published As

Publication number Publication date
WO2006057885A3 (en) 2006-06-29
MX2007006546A (es) 2007-08-17
MX2007006261A (es) 2007-07-10
US7241750B2 (en) 2007-07-10
US7241752B2 (en) 2007-07-10
AU2005309790B2 (en) 2012-03-08
DE602005021538D1 (de) 2010-07-08
JP5161582B2 (ja) 2013-03-13
JP2008520704A (ja) 2008-06-19
ATE469127T1 (de) 2010-06-15
AU2005309805B2 (en) 2011-06-09
NZ555277A (en) 2010-12-24
EP1846370B1 (de) 2010-06-02
MX2007006262A (es) 2007-07-10
WO2006057885A2 (en) 2006-06-01
JP5043673B2 (ja) 2012-10-10
US7741313B2 (en) 2010-06-22
NZ555278A (en) 2010-12-24
EP1817279B1 (de) 2010-05-26
AU2005309806A1 (en) 2006-06-01
CA2588401C (en) 2013-02-12
JP2008520690A (ja) 2008-06-19
WO2006057900A3 (en) 2006-07-06
ES2344989T3 (es) 2010-09-13
EP1828114A2 (de) 2007-09-05
CA2588410A1 (en) 2006-06-01
US20060111321A1 (en) 2006-05-25
WO2006057901A2 (en) 2006-06-01
US20070249568A1 (en) 2007-10-25
EP1846370A2 (de) 2007-10-24
CA2588396A1 (en) 2006-06-01
DE602005020842D1 (de) 2010-06-02
AU2005309790A1 (en) 2006-06-01
AU2005309806B2 (en) 2012-03-08
US20060111330A1 (en) 2006-05-25
US20070259838A1 (en) 2007-11-08
WO2006057901A3 (en) 2006-07-13
CA2588410C (en) 2013-04-02
EP1817279A2 (de) 2007-08-15
NZ555282A (en) 2010-12-24
EP1828114B1 (de) 2010-04-21
WO2006057900A2 (en) 2006-06-01
ES2346774T3 (es) 2010-10-20
US7704982B2 (en) 2010-04-27
CA2588401A1 (en) 2006-06-01
JP2008520705A (ja) 2008-06-19
ATE465144T1 (de) 2010-05-15
ES2347058T3 (es) 2010-10-25
US7241748B2 (en) 2007-07-10
US8232263B2 (en) 2012-07-31
US20060116351A1 (en) 2006-06-01
CA2588396C (en) 2013-04-23
US20070249569A1 (en) 2007-10-25
AU2005309805A1 (en) 2006-06-01
ATE469883T1 (de) 2010-06-15

Similar Documents

Publication Publication Date Title
ATE469883T1 (de) 2-methylen-19-nor-1alpha-hydroxy-17- enhormopregnacalziferol und anwendungen davon
MX2007006263A (es) Analogos 2a-metil y 2??-metil de 19,26,27-trinor-(20s)-1a- hidroxivitamina d3 y sus usos.
DE60215225D1 (de) Alpha-hydroxy-2-methylen-10-nor-pregnacalciferol und seine anwendungen
DE602005021245D1 (de) 2-methylen-19,26,27-trinor-(20s)-1-alpha-hydroxyvitamin d3 and dessen verwendungen
WO2006057899A3 (en) 2alpha-methyl-19-nor-(20s)-1alpha-hydroxy-bishomopregnacalciferol and its uses
PT1315504E (pt) 1-alfa-hidroxi-2-metileno-19-nor-homopregnacalciferol e suas aplicacoes terapeuticas
ATE415164T1 (de) (20s)-1alpha-hydroxy-2alpha-methyl und 2beta- methyl-19-nor vitamin d3 und ihre verwendung
MX2009003241A (es) Analogos de 2-metilen-(20r,25s)-19,27-dinor-(22e)-vitamina d.
ATE472528T1 (de) 2-methylen-18,19-dinor-1alfa-hydroxy- homopregnacalciferol und dessen verwendungen
ATE552239T1 (de) 2-methylen-20-methyl-19,24,25,26,27-pentanor- vitamin-d-analoga
MX2010007264A (es) Análogos de vitamina d 2-metilen-(20s, 25r)-19, 26-dinor.
ATE552238T1 (de) 2-methylen-(20s,25s)-19,27-dinor-(22e)-vitamin- - analoga
WO2010006125A3 (en) 2-methylene-19,26-dinor-(20r,22e,25r)-vitamin d analogs
WO2010006169A3 (en) 2-methylene-19, 26-dinor-(20s, 22e, 25r)-vitamin d analogs
WO2010006172A3 (en) 2-methylene-20(21)-dehydro-19-nor-vitamin d analogs
WO2006057902A3 (en) 2alpha-methyl-19-nor-1alpha-hydroxy-homopregnacalciferol and its uses
WO2010006135A3 (en) 2-methylene-(17z)-17(20)-dehydro-19,21-dinor-vitamin d analogs
WO2010006162A3 (en) 2-methylene-(20e)-20(22)-dehydro-19-nor-vitamin d analogs
WO2009086439A3 (en) 2-methylene-(20s,25s)-19,26-dinor-vitamin d analogs